Challenges assessing clinical endpoints in early Huntington disease. - Wikidata - wikimedia - TriplyDB

Challenges assessing clinical endpoints in early Huntington disease.

Challenges assessing clinical endpoints in early Huntington disease.

http://www.wikidata.org/entity/Q34299924

about

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology The search for sensitive biomarkers in presymptomatic Huntington disease.Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.QEEG Measures in Huntington's Disease: A Pilot Study.Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD.Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease Longitudinal Change in Gait and Motor Function in Pre-manifest Huntington's Disease.Age-at-onset in Huntington disease.Onset of Huntington's disease: can it be purely cognitive?Everyday cognition in prodromal Huntington disease WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease Indexing disease progression at study entry with individuals at-risk for Huntington disease Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues.Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease.Development of the Huntington disease work function scale Functional impairment in progressive supranuclear palsy Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD Refining the diagnosis of Huntington disease: the PREDICT-HD study.Clinical predictors of driving status in Huntington's disease.8OHdG as a marker for Huntington disease progression A systematic review and meta-analysis of clinical variables used in Huntington disease research.Chorea associated with Huntington's disease: to treat or not to treat?Validation of a prognostic index for Huntington's disease.Everyday Functioning in Huntington's Disease: A Laboratory-Based Study of Financial Management Capacity.Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

P2860

Q24621818-9604E054-2C5C-4197-AC92-6D88359EAB4E Q27691292-A3B37A3C-A55C-49C4-B450-AFBDE87C3EF1 Q30581974-CD49EF3F-B16A-48E8-96F4-4144808FE041 Q30631995-9594CE40-E5A9-4CC2-86BE-7838DA9F4F7F Q30644807-3EC8046C-B81E-4BEB-AF36-18AFA376140D Q33734662-755CB4F9-9B17-4E33-930C-86645B581F2F Q34013839-CDBFE44E-92E5-4727-84CF-BBB2AADC80E5 Q34021833-45837B68-19A9-4645-B305-6E0289C84690 Q34050993-DFBB7F40-D96E-41E8-9CD7-6074EDE94EB7 Q34210139-B016AD11-80C3-49E5-BDA1-FA3F88148147 Q34322005-B90A18BD-BF31-4D1E-819A-46F628CAFD05 Q34861585-6789829E-555D-4A4E-9DFC-5D37A470AE8D Q35150473-BED79A69-67B4-4536-8DBB-DAD134E5AFBD Q35216637-40BB8582-B83D-4C43-8E57-DAA30F234FB9 Q35738853-2B952B21-BB7F-4D23-A576-16D54967E002 Q35997096-AEB67A3B-8D6A-4A5E-B840-B76EC4F20F75 Q36184559-03AF34C1-1CB8-4E4C-9036-85E50EF185FB Q36303727-38388BAB-8922-434C-9CBA-15D99499E43C Q36659574-14F8842A-6CD8-40DF-B8AC-72EF532C3A0E Q36696620-63326580-24B9-44C9-A1C5-CCD00B9BFEE7 Q36732557-D992AACC-9E4F-4FC1-AD8A-5E778F18DE78 Q36802731-F6928A81-9E9D-45ED-B2B6-5A1EA766256C Q37199696-279F7E49-3059-461E-81CB-C0E7DE8BD380 Q38154195-4E630AB2-A6F8-4E3F-8C9D-F4C4196004BC Q38243296-09D583A6-EB91-4473-A77A-AC90C052560B Q38790095-CDE345D5-0DFB-4B15-A198-D81CC41E8623 Q45294436-315F52C5-03B8-4B6E-85F1-523D95862BD8 Q45304624-46FB8EA9-F080-471B-AEAF-505B9DC538F0 Q45305974-8D72B0A4-9146-4B22-8451-524E189E9521 Q52311573-77B91A20-08BF-4CB4-A0DE-28AE00711C48 Q52721984-D2860B7B-A455-4583-8269-2EDBA20927B3

P2860

Challenges assessing clinical endpoints in early Huntington disease.

http://www.wikidata.org/entity/Q34299924

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Challenges assessing clinical endpoints in early Huntington disease.

@ast

Challenges assessing clinical endpoints in early Huntington disease.

@en

Challenges assessing clinical endpoints in early Huntington disease.

@nl

type

label

Challenges assessing clinical endpoints in early Huntington disease.

@ast

Challenges assessing clinical endpoints in early Huntington disease.

@en

Challenges assessing clinical endpoints in early Huntington disease.

@nl

prefLabel

Challenges assessing clinical endpoints in early Huntington disease.

@ast

Challenges assessing clinical endpoints in early Huntington disease.

@en

Challenges assessing clinical endpoints in early Huntington disease.

@nl

P1433

Q34299924-3F35F49B-18DF-4687-BED8-11335CA28005

P1476

Q34299924-D981D9C9-9209-4977-91C1-2386BC167CD2

P2093

Q34299924-1561DED7-3190-4D92-9499-BBAE3ED0E689

Q34299924-4E31F8CF-E10E-4450-BDB2-B80616C37690

Q34299924-54810042-B09E-4473-AA0C-393BC9C6C265

Q34299924-5F304370-707D-4F70-90D5-FF58812A3F17

Q34299924-83A56447-0377-4C9B-A801-6BB6D10CBCE8

Q34299924-B3DD5DF3-95B3-4895-B300-C36DF3AD9966

Q34299924-F5EE5F8F-C207-419B-A53A-9F24D8DB7F5C

P2860

Q34299924-084B9941-E354-4128-9161-6BA1D9793E03

Q34299924-0AB179EE-B683-4612-A5D7-C21C103C875D

Q34299924-2AE40D7C-EC48-4803-94B7-7841555C7545

Q34299924-2C9E9471-CB97-45C8-A293-B5CEE43D2433

Q34299924-397D819E-7EFB-4283-8DDC-642784CE4EEC

Q34299924-4124EA1D-E9E9-46FA-848F-5E1466754092

Q34299924-4C099EF4-C741-41C5-BE55-C7ABF6162865

Q34299924-5D0041E2-9B9F-480F-A4FC-C4EE3F527DB7

Q34299924-619344E4-6C0E-4DEC-A242-ADDA787F8F16

Q34299924-61D79D3C-5D99-4B76-AB15-E801529D34DB

P304

Q34299924-0AAB335D-C183-4F20-B1DA-001B013F2A66

P31

Q34299924-780D80A8-7101-41EF-8B88-0236C7EA1994

P356

Q34299924-2F3375EE-8B0B-45FF-9BB7-498C7B0D930E

P407

Q34299924-7468D303-175F-407C-B6E6-D977A3BAF9C8

P433

Q34299924-52E92139-D9AF-4F72-80F9-882328D2320A

P478

Q34299924-92C0E5C6-291D-4E91-ABDE-845A3B703764

P50

Q34299924-56177093-0CB3-40BF-825A-E43B50C15F28

Q34299924-8041DF52-499E-4846-87A4-5DA904BAA9C1

Q34299924-9370850A-7D31-4415-851B-2DAC613FF8D5

Q34299924-D2FD2D11-8352-4BAB-823C-203F058B6C50

Q34299924-DB343938-64EC-4FB5-A870-755BE73D6BBA

P577

Q34299924-8D1E458A-7256-44ED-9EF8-9F2AF197BAE8

P5875

Q34299924-0EF0ED1C-994B-40AA-BCD8-6C652F2BA6FB

P698

Q34299924-90A81D82-3B70-4B01-917A-E57BBCCB24BF

P921

Q34299924-DF1703CA-10BB-4805-8989-AD9BBBDEF985

P932

Q34299924-8C901A76-ACBA-4585-A416-1D110B2768B0

P356

P1433

Movement Disorders

P1476

Challenges assessing clinical endpoints in early Huntington disease.

@en

P2093

Chiachi Wang

http://www.w3.org/2001/XMLSchema#string

Daniel P van Kammen

http://www.w3.org/2001/XMLSchema#string

Kevin Duff

http://www.w3.org/2001/XMLSchema#string

Leigh Beglinger

http://www.w3.org/2001/XMLSchema#string

Martha Nance

http://www.w3.org/2001/XMLSchema#string

PREDICT-HD Investigators of the Huntington Study Group

http://www.w3.org/2001/XMLSchema#string

Sheila Simpson

http://www.w3.org/2001/XMLSchema#string

P2860

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Neuropsychiatric aspects of Huntington's disease.

Behavioural abnormalities contribute to functional decline in Huntington's disease.

Measures and markers in amyotrophic lateral sclerosis.

Earliest functional declines in Huntington disease

Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

Symptomatic treatment of Huntington disease

P304

2595-2603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23337

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Janet K. Williams

Jane S. Paulsen

Douglas R Langbehn

Roger A. Barker

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45152732

http://www.w3.org/2001/XMLSchema#string

P698

20623772

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2978744

http://www.w3.org/2001/XMLSchema#string